Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).

Tedesco, Karen L.; Blum, Joanne L.; Gonçalvès, Anthony; Lubiński, Jan; Osborne, CK; Lardelli, Pilar; Tercero, Juan Carlos; Florez, Amalia; Holmes, Frankie A.; Delaloge, Suzette

doi:10.1200/jco.2011.29.15_suppl.1125

Cited by 10 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized trials are currently addressing the activity of platinum compounds in comparison with conventional agents in patients with TNBC and subpopulations within TNBC (NCT00532727 and NCT00861705 [118,119]. Newer cytotoxic agents have been investigated and have shown some limited activity in those with heavily pretreated advanced TNBC (see Table 2) [120][121][122].…”

Section: Cytotoxic Chemotherapy Agent Selectionmentioning

confidence: 99%

Molecular heterogeneity of triple-negative breast cancer and its clinical implications

Irshad

Ellis

Tutt

2011

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Section: Cytotoxic Chemotherapy Agent Selectionmentioning

confidence: 99%

Molecular heterogeneity of triple-negative breast cancer and its clinical implications

Irshad

Ellis

Tutt

2011

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Its unique mechanism of action and the promising results from phase 1 and phase 2 clinical trials [65][66][67] involving more than 230 patients led to a phase 2 study of brostallicin (NCT01091454, currently suspended) in combination with cisplatin in patients with refractory metastatic TNBC. Others agents examined in early phase analysis have shown some activity in HER2-positive and BRCA1/2 mutation-associated breast cancer, but not particular efficacy in unselected TNBC [68].…”

Section: Minor Groove Bindersmentioning

confidence: 97%

Treatment of Metastatic Triple-Negative Breast Cancer

Glendenning

Irshad

Tutt

2012

Curr Breast Cancer Rep

View full text Add to dashboard Cite

The triple-negative breast cancer (TNBC) phenotype, defined as the lack of estrogen and progesterone hormone receptors and the HER2 receptor, represents approximately 15% to 20% of all breast cancer cases. Challenges faced in management of these patients arise from the heterogeneity of TNBC and the absence of well-defined molecular targets. Subgroups derive significant benefit from cytotoxics however, patients with TNBC have higher rates of distant recurrence and a poorer prognosis than women with other breast cancer subtypes overall. Currently, cytotoxic chemotherapy is the only systemic treatment option at all stages of disease, and rational drug selection based on tumor biology remains an aspiration. In the context of relapse, the most efficacious regimens remain undefined and the typical clinical picture is one of rapid disease progression and little durable benefit to therapy. This article reviews current approaches in metastatic TNBC and considers novel therapies in development that may improve the outlook for those with this disease.

show abstract

“…When evaluated in heavily pretreated MBC patients with germline BRCA1 and BRCA2 mutations, trabectedin treatment every 3 weeks was found to lead to PR in 6 out of 35 patients (17%), with median PFS of 3.9 months . Similarly, a phase II trial of trabectedin showed activity in BRCA1/2 mutation carrier patients with pretreated MBC, with 4 out of 29 patients (14%) achieving PR and median PFS of 3.3 months .…”

Section: Trabectidinmentioning

confidence: 98%

Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes

2017

View full text Add to dashboard Cite

Molecular testing allows for identification of germline mutations that place individuals at high risk for breast cancer and that are associated with distinct histopathology and molecular characteristics that define the invasive breast cancer cases that these patients develop. These unique characteristics may ultimately provide rational targets for systemic treatments with improvements in both morbidity and efficacy. Identification of patients with these germline mutations is important for not only appropriate screening and prophylaxis, but knowledge of therapies specifically targeting several of the most common hereditary breast cancer syndromes is essential to ensure appropriate treatment of invasive breast cancers in these patients.

show abstract

Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).

Cited by 10 publications

References 0 publications

Molecular heterogeneity of triple-negative breast cancer and its clinical implications

Molecular heterogeneity of triple-negative breast cancer and its clinical implications

Treatment of Metastatic Triple-Negative Breast Cancer

Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes

Contact Info

Product

Resources

About